LncRNA | MiRNA | Gene | Gene name | Pathway Name | Description | Title | Disease/Tissue | Journal | PubMed ID |
ROR | miR-145 | FSCN1 | FSCN1;FAN1;HSN;SNL;p55 | details | details
The function of linc-ROR exerted in LAD cells depended on the sponging of miR-145, therefore, releasing the miR-145 target FSCN1, and thus contributing to the acquisition of chemoresistance and EMT phenotypes of docetaxel-resistant LAD cells.
|
details
Long noncoding RNA ROR regulates chemoresistance in docetaxel-resistant lung adenocarcinoma cells via epithelial mesenchymal transition pathway
|
Lung Adenocarcinoma | Oncotarget | 28388536 |
ROR | miR-145 | p53 | TP53;BCC7;LFS1;P53;TRP53 | details
MAPK signaling pathway;Cell cycle;Epstein-Barr virus infection;p53 signaling pathway;PI3K-Akt signaling pathway;Apoptosis;Thyroid cancer;Melanoma;Basal cell carcinoma;Measles;Chronic myeloid leukemia;Wnt signaling pathway;Neurotrophin signaling pathway;HTLV-I infection;Non-small cell lung cancer;Proteoglycans in cancer;Prostate cancer;Amyotrophic lateral sclerosis (ALS);Transcriptional misregulation in cancer;Pathways in cancer;Pancreatic cancer;Huntington's disease;Hepatitis C;Colorectal cancer;Glioma;Bladder cancer;Endometrial cancer;Hepatitis B;Viral carcinogenesis;Small cell lung cancer;Herpes simplex infection
|
details
Activity of the p53/miR-145 pathway may help explain the role of lincRNA-ROR for stress-induced regulation in CRC therapy.
|
details
The long noncoding RNA-ROR promotes the resistance of radiotherapy for human colorectal cancer cells by targeting the p53/miR-145 pathway
|
Colorectal Cancer | J Gastroenterol Hepatol | 27696511 |
ROR | miR-145 | Sox2 | SOX2;ANOP3;MCOPS3 | details
Hippo signaling pathway
|
details
The experimental results indicate that lncRNA-ROR effectively maintains Sox2 gene expression through competitive binding to miR-145, achieving pluripotency maintenance in HuAECs and regulation of their directed β islet-like cell differentiation efficiency.
|
details
miR-145 modulates lncRNA-ROR and Sox2 expression to maintain human amniotic epithelial stem cell pluripotency and β islet-like cell differentiation efficiency
|
Human Amniotic Epithelial Stem Cells | Gene | 27346547 |
ROR | miR-205 | ZEB1 | ZEB1;AREB6;BZP;DELTAEF1;FECD6;NIL2A;PPCD3;TCF8;ZFHEP;ZFHX1A | details
Transcriptional misregulation in cancer
|
details
Compared with the MCF7 cells, the MCF7-ROR cells had remarkably higher proliferation rates, down-regulated E-cadherin and miR-205 expressions, as well as increased vimentin, invasive ability, and mRNA expression of ZEB1 and ZEB2. Compared with the MCF7/TR5 and MDA-MB-231 cells, up-regulated E-cadherin and miR-205 expression, down-regulated expression of vimentin, ZEB1, and ZEB2 mRNA, and decreased invasive ability were observed in the MCF7/TR5 ROR-siRNA and MDA-MB-231 ROR-siRNA cells.
|
details
Effects of long noncoding RNA-ROR on tamoxifen resistance of breast cancer cells by regulating microRNA-205
|
Breast Cancer | Cancer Chemother Pharmacol | 28063065 |
ROR | miR-205 | ZEB2 | ZEB2;HSPC082;SIP-1;SIP1;SMADIP1;ZFHX1B | details | details
Specifically, linc-ROR prevented the degradation of mir-205 target genes, including the EMT inducer ZEB2.
|
details
LincRNA-ROR induces epithelial-to-mesenchymal transition and contributes to breast cancer tumorigenesis and metastasis
|
Breast Cancer | Cell Death Dis | 24922071 |
ROR | miR-205 | ZEB2 | ZEB2;HSPC082;SIP-1;SIP1;SMADIP1;ZFHX1B | details | details
Compared with the MCF7 cells, the MCF7-ROR cells had remarkably higher proliferation rates, down-regulated E-cadherin and miR-205 expressions, as well as increased vimentin, invasive ability, and mRNA expression of ZEB1 and ZEB2. Compared with the MCF7/TR5 and MDA-MB-231 cells, up-regulated E-cadherin and miR-205 expression, down-regulated expression of vimentin, ZEB1, and ZEB2 mRNA, and decreased invasive ability were observed in the MCF7/TR5 ROR-siRNA and MDA-MB-231 ROR-siRNA cells.
|
details
Effects of long noncoding RNA-ROR on tamoxifen resistance of breast cancer cells by regulating microRNA-205
|
Breast Cancer | Cancer Chemother Pharmacol | 28063065 |